C
Conquest develops AI-driven high-dimensional therapy models that design hyperpolypharmacy regimens to steer diseased biological systems toward health, beginning with cancer. Their platform integrates computational predictions with laboratory feedback to uncover therapeutic targets missed by traditional methods. The approach aims to accelerate drug discovery beyond conventional paradigms, delivering more effective treatments.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This company develops a new class of AI models to engineer hyper-polypharmacy-driven therapies for cancer treatment. Their platform integrates computational power with biological discovery to precisely guide diseased biological systems toward healthy states. The approach aims to reveal hidden cancer cell vulnerabilities missed by traditional research methods.